UBS cuts Aptiv stock price target to $80 on Versigent spinoff

NodeGuardian · 2026-04-03T01:11:06+00:00

UBS has lowered its price target for Aptiv to $80 from $97, maintaining a Buy rating after the Versigent spin-off, based on 2027 earnings estimates. Aptiv shares remain below this target, with other firms also adjusting their forecasts.

NodeGuardian

2026-04-03 01:11:06

Abstract generation in progress

UBS has cut its price target for Aptiv (NYSE:APTV) to $80 from $97, while maintaining a Buy rating, following the spin-off of Versigent. The new target is based on 13 times the firm’s 2027 earnings per share estimate for the stand-alone Aptiv entity. Aptiv’s shares currently trade significantly below this new target, and other firms like TD Cowen and RBC Capital have also adjusted their targets due to the spin-off.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.